ArticlemAbs
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Robert J Benschop et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
pooled itcites it